Far out just read the question that is one hardcore no on Rem-L from the author. Seems to be focusing on the missed endpoints alot. Does the drawn target analogy have meaning in this context as we have found Rem-L to be effacious in the covid ARDS extension. Some rebuttal points that immediately come to mind are consistency and dosage has been improved since the original trials at Osiris? Or am I getting confused with another label in the MSB range.
Far out just read the question that is one hardcore no on Rem-L...
-
- There are more pages in this discussion • 12,602 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43856 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 66000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |